新聞Morphotek, Inc. partnered with Rockefeller on Dec 11th '17.Morphotek ®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a Sponsored Research Agreement (SRA) with The Rockefeller University to expand its research efforts around the mechanisms by which the CA125 tumor shed antigen suppresses immune-based therapies.
新聞Morphotek, Inc. launched Antibody Drug Conjugate on Apr 2nd '17.Morphotek®, Inc., a subsidiary of Eisai Inc., announced today the launch of its Antibody Drug Conjugate (ADC) Services business based on its proprietary REsidue-SPEcific Conjugation TechnologyTM (RESPECTTM) and eribulin-linker toxin platforms.
新聞Morphotek, Inc. signed new client Eurofarma Laboratórios S.A on Oct 4th '16.TOKYO, Oct 4, 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that its research subsidiary Morphotek, Inc. has signed an exclusive licensing agreement with Eurofarma Laboratorios S.A. to develop and commercialize the monoclonal antibody farletuzumab (development code: MORAb-003) as a potential anticancer agent in Latin America.
